TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22928719
Drug: Miltefosine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (150 mg daily for 4 weeks)
Study: 20216222
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (400, 600 or 800 mg/day)
Study: 14666762
Drug: Chinese Compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese Compound Changjitai (CJT)
Study: 10713623
Drug: MEL-CY (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL-CY (cyclophosphamide 120 mg/kg + melphalan 200 mg/m2)
Study: 10713623
Drug: MEL-TBI (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL-TBI (total body irradiation 1125 cGy + melphalan 140 mg/m2)
Study: 1497051
Drug: Esterified estrogen
Normalized name: Esterified estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogen 0.625 mg (Estratab)
Study: 1497051
Drug: Esterified estrogen
Normalized name: Esterified estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esterified estrogen 0.625 mg plus 1.25 mg methyltestosterone (Estratest H.S.)
Study: 1497051
Drug: Conjugated estrogen
Normalized name: Conjugated estrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated estrogen 0.625 mg (Premarin)
Study: 6689276
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 500 mg of salicylamide
Study: 6689276
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 500 mg of salicylamide
Study: 6689276
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1500 mg of salicylamide
Study: 6689276
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 1500 mg of salicylamide
Study: 6689276
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of salicylamide
Study: 6689276
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of salicylamide
Study: 22584017
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisone (6.25 mg/day) co-medication with methotrexate (MTX)
Study: 16035056
Drug: Duloxetine 60-mg
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-mg QD
Study: 10534515
Drug: Clexane (enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clexane (enoxaparin sodium) 1 mg/kg body weight
Study: 10534515
Drug: Clexane (enoxaparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clexane (enoxaparin sodium) 0.69 mg/kg (after dose reduction)
Study: 10534515
Drug: Standard unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unfractionated heparin
Study: 7781662
Drug: Candoxatril treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril treatment on high sodium diet
Study: 7781662
Drug: Candoxatril treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril treatment on low sodium diet
Study: 2191189
Drug: Continuous intraperitoneal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intraperitoneal insulin (CIPII)
Study: 31045840
Drug: Oxycodone 2×ED95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 2×ED95 (0.182 mg/kg)
Study: 31045840
Drug: Oxycodone ED95
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone ED95 (0.091 mg/kg)
Study: 31045840
Drug: Oxycodone 0.269
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone 0.269 mg/kg (recalculated ED95)
Study: 28671089
Drug: 2% liranaftate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% liranaftate ointment
Study: 23478248
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 600 mg plus three-drug regimen (pantoprazole 40 mg BD, ciprofloxacin 500 mg BD, bismuth subcitrate 120 mg two tablets BD)
Study: 23478248
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus three-drug regimen (pantoprazole 40 mg BD, ciprofloxacin 500 mg BD, bismuth subcitrate 120 mg two tablets BD)
Study: 15386160
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU vitamin D3 plus 1 g calcium
Study: 9044475
Drug: rt‐PA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt‐PA plus heparin (H) (n = 10)
Study: 9044475
Drug: Heparin (H)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (H) alone (n = 10)
Study: 12544454
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril
Study: 3630891
Drug: Aspirin pretreatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin pretreatment (3.6 mg/kg lysine salt of acetylsalicylic acid, corresponding to 2 mg/kg aspirin)
Study: 24821586
Drug: linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5mg daily
Study: 22552566
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ramipril 10 mg + telmisartan 80 mg)
Study: 18711936
Drug: Corticosteroids (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisolone 40 mg daily tapered to 5 mg over 12 weeks) + MB-MDT
Study: 17045906
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil at 7.5 mug
Study: 17045906
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil at 30 mug
Study: 17045906
Drug: Inhaled treprostinil
Normalized name: treprostinil Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled treprostinil at 15 mug with varying pulses (18, 9, 3, 2, 1)
Study: 10894582
Drug: Propofol (20‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (20‐120 mg) and fentanyl (0.25‐1.5 mg)
Study: 10894582
Drug: Midazolam (2‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (2‐6 mg) and meperidine (25‐75 mg)
Study: 3904410
Drug: Slow tapering
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow tapering of methadone
Study: 31985746
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with mean arterial blood pressure (MABP) less than 70 mm Hg for a minimum of 10 minutes
Study: 31985746
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with mean arterial blood pressure (MABP) less than 70 mm Hg for a continuous episode of minimum 20 minutes
Study: 31985746
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with mean arterial blood pressure (MABP) greater than 90 mm Hg for a minimum of 45 minutes
Study: 31985746
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with mean arterial blood pressure (MABP) greater than 90 mm Hg for a continuous episode of minimum 115 minutes
Study: 24872027
Drug: Nicotine oral
Normalized name: nicotine Oral Lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine oral spray (1mg of nicotine free base per spray) plus nicotine patch
Study: 24872027
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo spray plus nicotine patch
Study: 23649050
Drug: Dexamethasone 1
Normalized name: dexamethasone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1 mg every 8 hours for 3 days
Study: 23649050
Drug: Serratiopaptidase 10
Normalized name: serratiopeptidase 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratiopaptidase 10 mg every 8 hours for 3 days
Study: 15566926
Drug: Estrogen-progestin replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin replacement therapy
Study: 15828615
Drug: Minimal dose
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal dose of estrogens
Study: 12461301
Drug: Chlorthalidone, 12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone, 12.5-25 mg/d (n=15,255)
Study: 12461301
Drug: Amlodipine, 2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine, 2.5-10 mg/d (n=9048)
Study: 12461301
Drug: Lisinopril, 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril, 10-40 mg/d (n=9054)
Study: 10492100
Drug: Intensive regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive regimen (3000 microg dinoprostone given three times daily)
Study: 10492100
Drug: Standard regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regimen (3000 microg dinoprostone once daily)
Study: 8758286
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether (Art) 6 mg/kg followed by 3 repeated doses every 15 days
Study: 6688500
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone sodium phosphate (0.6 mg/kg)
Study: 23947690
Drug: Topical Arnica
Normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Arnica
Study: 11196518
Drug: Individually attended
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually attended treatment
Study: 7977319
Drug: r‐HuEPO (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (50 U/kg subcutaneously three times weekly)
Study: 7977319
Drug: r‐HuEPO (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: r‐HuEPO (treatment group)
Study: 30700564
Drug: Continuous Infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Infusion of Vancomycin (CIV)
Study: 30700564
Drug: Intermittent Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent Infusion of Vancomycin (IIV)
Study: 21773588
Drug: Chicory inulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chicory inulin (20 g day(-1))
Study: 10355845
Drug: Fat emulsion
Normalized name: FAT EMULSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat emulsion (30% of total calories) administered from day of operation to POD 7
Study: 10355845
Drug: Glucose as
Normalized name: Publix Glucose Assorted Flavors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose as a non-protein calorie source administered from day of operation to POD 7
Study: 7213520
Drug: Heroin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (3 mg/70 kg)
Study: 7213520
Drug: Heroin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (6 mg/70 kg)
Study: 7213520
Drug: Heroin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (12 mg/70 kg)
Study: 8071850
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg/70 kg)
Study: 7213520
Drug: Morphine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (20 mg/70 kg)
Study: 30278495
Drug: 40 mL of
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mL of 0.375% ropivacaine mixed with 1 μg/kg dexmedetomidine (group D)
Study: 30278495
Drug: 40 mL of
Normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mL of 0.375% ropivacaine (group C)
Study: 26499503
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care provided by a certified diabetes-educator pharmacist
Study: 12815800
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy with at least three drugs
Study: 9813401
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 2,400 mg/day)
Study: 8878083
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g sorbitol and 20 g glucose
Study: 8878083
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g sorbitol and 9 g lipids
Study: 8878083
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g sorbitol alone
Study: 7028921
Drug: Timolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (5 mg twice daily)
Study: 30528828
Drug: Apremilast 40
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 40 mg twice daily (APR40)
Study: 30528828
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily (APR30)
Study: 21372124
Drug: Sagopilone 16
Normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone 16 mg/m² as a 3-h i.v. infusion every 21 days for up to 6 weeks
Study: 21372124
Drug: Sagopilone 16
Normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone 16 mg/m² as a 0.5-h i.v. infusion every 21 days for up to 6 weeks
Study: 21372124
Drug: Sagopilone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sagopilone (both infusion schedules)
Study: 19998333
Drug: Standardized Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Care group (SCG) - directed to a resource room for women with chemotherapy-related alopecia
Study: 16393218
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of ketorolac trometamol (KT) administered intravenously as premedication 30 min prior to procedure
Study: 16393218
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline) administered intravenously as premedication 30 min prior to procedure
Study: 11925518
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (400% above the seizure threshold) right unilateral (RUL) ECT
Study: 11925518
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose (150% above seizure threshold) RUL ECT
Study: 11925518
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (just above seizure threshold) bifrontal (BF) ECT
Study: 2667310
Drug: Urapidil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (25 or 50 mg)
Study: 55890
Drug: Methimazole 40
Normalized name: methimazole 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 40 mg per day
Study: 28244906
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide administration for 6 months postoperatively
Study: 25304755
Drug: Repeated dose
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated dose 4+8+4mg betamethasone
Study: 25304755
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose 16mg betamethasone
Study: 25304755
Drug: Betamethasone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (both doses)
Study: 21223344
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 2 weeks (q2w)
Study: 21223344
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg every 4 weeks (q4w)
Study: 19947366
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (including mastectomy, neoadjuvant and adjuvant chemohormonal and radiotherapy)
Study: 17854247
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zonisamide and bupropion
Study: 11304902
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg p.o. bid
Study: 9219782
Drug: Stonetome combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stonetome combination catheter
Study: 7902021
Drug: Deflazacort 30
Normalized name: deflazacort 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 30 mg/d
Study: 7902021
Drug: Deflazacort 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 60 mg/d
Study: 7902021
Drug: Deflazacort 6
Normalized name: deflazacort 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort 6 mg/d
Study: 27256922
Drug: MK‐1064 (OX2R
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK‐1064 (OX2R antagonist)
Study: 27256922
Drug: Dual orexin
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual orexin receptor antagonists (for comparison)
Study: 25614171
Drug: 3-month prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 3 months, then tapered)
Study: 25614171
Drug: 6-month prednisolone
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month prednisolone treatment (0.5 mg·kg(‐1)·day(‐1) for 6 months, then tapered)
Study: 25614171
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (3-month and 6-month prednisolone)
Study: 19056708
Drug: Newer antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antiretroviral therapies
Study: 19056708
Drug: Earlier antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier antiretroviral therapies
Study: 10769553
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (1 g)
Study: 10769553
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (1 g)
Study: 10769553
Drug: Mepivacaine infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine infiltration (0.2 ml of 1%)
Study: 9314631
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro in combination with sulfonylureas
Study: 11398073
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy
Study: 24336783
Drug: OAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAC treatment in sinus rhythm (SR) subgroup
Study: 21953589
Drug: Prednisolone 60
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60 mg/day
Study: 21953589
Drug: Prednisolone 30
Normalized name: prednisolone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 30 mg/day
Study: 18301121
Drug: Active treatments
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatments using the Sheehan Disability Scale (SDS)
Study: 18301121
Drug: Inactive treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive treatments using the Sheehan Disability Scale (SDS)
Study: 15496867
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) >or=50 g
Study: 9474110
Drug: Home-based physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based physical therapy (5 sessions)
Study: 9474110
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy strategies incorporated into interactive play activities
Study: 7603607
Drug: 100 IU/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 IU/day daily for 30 days every other month (cyclically)
Study: 7603607
Drug: Cyclic and
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic and continuous treatment groups at the same dosage
Study: 7603607
Drug: S‐calcitonin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐calcitonin therapy cessation
Study: 2743348
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg trazodone daily
Study: 2743348
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg amitriptyline daily
Study: 2743348
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg haloperidol daily
Study: 2743348
Drug: placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily
Study: 21174533
Drug: Bendamustine 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 120 mg/m² on days 1 and 2 of each 21-day cycle for six to eight cycles
Study: 2210673
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg/day)
Study: 17134849
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg L-dopa plus 100 mg carbidopa (Sinemet CR)
Study: 17134849
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg L-dopa plus 200 mg carbidopa (Sinemet CR)
Study: 7880610
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion (c.i.v.) of recombinant human IL-2 (rIL-2)
Study: 7880610
Drug: Subcutaneous (s.c.)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (s.c.) injections of recombinant human IL-2 (rIL-2)